The rise of AI has been accompanied by an explosion of processing horsepower.
News, analysis and comment from the Financial Times, the worldʼs leading global business publication.
Category: business
Early in the testing phase of Apple’s M1 chipset, a milestone new product for the company, the processor was installed in a batch of Mac computers and given to staffers working on applications that demanded heavy processing power. It was a pivotal moment: the first time Apple had made its own chip for any of its computers, shifting away from years of using a one-size-fits-all option from Intel.
After multiple teams tested the devices for a few hours while working on tasks, they reported lightning-fast performance but nearly all flagged an apparent problem. The MacBook Pro’s battery indicator, featured on the upper right hand corner of the computers, was broken. It had barely moved despite running power-hungry programs, the company told CNN Business.
The gag, of course, is that the battery indicator was working just fine. The M1 chip was so efficient, according to Apple, that it showed no real strain — one of several major selling points for products that now carry the chip. (Apple promises 20 hours of battery life for its 13-inch M1 MacBook Pro — what it says is the longest battery in any Mac to date).
There’s some really interesting CRISPR news out today, and it’s likely to be a forerunner of much more news to come. A research team has demonstrated what looks like robust, long-lasting effects in a primate model after one injection of the CRISPR enzymatic machinery. There have been plenty of rodent reports on various forms of CRISPR, and there are some human trials underway, but these is the first primate numbers that I’m aware of.
The gene they chose to inactivate is PCSK9, which has been a hot topic in drug discovery for some years now. It’s a target validated by several converging lines of evidence from the human population (see the “History” section of that first link). People with overactive PCSK9 have high LDL lipoproteins and cholesterol, and people with mutations that make it inactive have extremely low LDL and seem to be protected from a lot of cardiovascular disease. There are several drugs and drug candidates out there targeting the protein, as well there might be.
It’s a good proof-of-concept, then, because we know exactly what the effects of turning down the expression of active PCSK9 should look like. It’s also got the major advantage of being mostly a liver target – as I’ve mentioned several times on the blog already, many therapies aimed at gene editing or RNA manipulation have a pharmacokinetic complication. The formulations used to get such agents intact into the body (and in a form that they can penetrate cells) tend to get combed out pretty thoroughly by the liver – which after all, is (among other things) in the business of policing the bloodstream for weird, unrecognized stuff that is then targeted for demolition by hepatocytes. Your entire bloodstream goes sluicing through the liver constantly; you’re not going to able to dodge it if your therapy is out there in the circulation. It happens to our small-molecule drugs all the time: hepatic “first pass” metabolism is almost always a factor to reckon with.
French businesses are betting on insects as food. We explore the off-limit foods that might soon be on our plates.
Check out VICE News for more: http://vicenews.com.
Follow VICE News here:
Facebook: https://www.facebook.com/vicenews.
Twitter: https://twitter.com/vicenews.
Tumblr: http://vicenews.tumblr.com/
Instagram: http://instagram.com/vicenews.
More videos from the VICE network: https://www.fb.com/vicevideo.
#VICENews #News
The need for more web watchmen spans from private businesses to government agencies, experts say, and most of the job openings are in California, Florida, Texas and Virginia. That means for anyone looking to switch careers and considering a job in cybersecurity, there’s no greater time than now to find work, the job trackers said.
“You don’t have to be a graduate of MIT to work in cybersecurity,” said Tim Herbert, executive vice president for research at CompTIA. “It just requires someone who has the proper training, proper certification and is certainly committed to the work.”
Dr Jamie L. Wells, MD — Director, Research Science Inst — Pediatrician, Medical Innovator, Educator
Posted in biotech/medical, bitcoin, business, education, health, policy, robotics/AI, science | Leave a Comment on Dr Jamie L. Wells, MD — Director, Research Science Inst — Pediatrician, Medical Innovator, Educator
Pediatrician, Medical Innovator, Educator — Dr. Jamie Wells, MD, FAAP — Director, Research Science Institute (RSI), Center for Excellence in Education, Massachusetts Institute of Technology (MIT) — Professor, Drexel University School of Biomedical Engineering, Science and Health Systems.
Dr. Jamie L. Wells, MD, FAAP, is an Adjunct Professor at Drexel University’s School of Biomedical Engineering, Science and Health Systems, where she has been involved in helping to spearhead the nation’s first-degree program focused on pediatric engineering, innovation, and medical advancement.
Dr. Wells is an award-winning Board-certified pediatrician with many years of experience caring for patients. With her BA with Honors from Yale, and her MD from Jefferson Medical College, Philadelphia, PA, she has served as a Clinical Instructor/Attending at NYU Langone, Mt. Sinai-Beth Israel and St. Vincent’s Medical Centers in Manhattan.
Dr. Wells also serves as Director of the Research Science Institute (RSI), at Center for Excellence in Education (CEE), a non-profit, 501©(3) organization, collaboratively sponsored with MIT bring together top U.S. and international high school students for an intensive, six-week summer program that provides students with the opportunity to conduct original, cutting-edge research.
Dr. Wells is on the leadership council of the Wistar Institute (the USA’s first independent biomedical research facility and certified cancer center), Ambassador of the Healthcare Global Blockchain Business Council, was a grant reviewer for the Susan G. Komen Community Grants Program, judged both the local, district and world robotics championships for Dean Kamen’s F.I.R.S.T. (For Inspiration & Recognition of Science & Technology) nonprofit, as well as the Miss America’s Outstanding Teen scholarship competition (for which she is now a member of its Board of Directors), and is the Chair of the Yale Alumni Health Network (YAHN).
Dr. Wells has a proven track record of success in communications on various platforms (e.g. BBC, Reuters TV, Fox News Channel, Discovery Health), routinely appearing as a medical expert and has published over 400 articles as director of medicine for an educational advocacy nonprofit.
Dr. Wells has broad ranging interests in patient safety and optimizing care delivery, bioethics, public health and policy, science communications, med-tech innovation, diagnosis and management of disease, identifying healthcare trends, bridging interdisciplinary knowledge gaps to prevent medical error and expedite discovery, thought integration of clinical practice and biomedical engineering approaches with an emphasis on patient-centered design, debunking medical myths and pediatrics.
Companies caught in the middle of the global semiconductor shortage, which is roiling the car business, are starting to see light at the end of the tunnel.
There’s a wide world of delivery logistics going on behind the scenes in America, one that’s become central to everyday life. And yet, most of us are completely oblivious to its environmental cost. But thanks to a handful of ambitious startups, there’s an electric revolution happening that may be perfectly suited to delivering us a cleaner future.
#Accelerate #EV #BloombergQuicktake.
——-
Like this video? Subscribe: http://www.youtube.com/Bloomberg?sub_confirmation=1
Become a Quicktake Member for exclusive perks: http://www.youtube.com/bloomberg/join.
QuickTake Originals is Bloomberg’s official premium video channel. We bring you insights and analysis from business, science, and technology experts who are shaping our future. We’re home to Hello World, Giant Leap, Storylines, and the series powering CityLab, Bloomberg Businessweek, Bloomberg Green, and much more.
Subscribe for business news, but not as you’ve known it: exclusive interviews, fascinating profiles, data-driven analysis, and the latest in tech innovation from around the world.
Visit our partner channel QuickTake News for breaking global news and insight in an instant.
Eight months on, the semiconductor shortage seems likely to stretch into 2022. Increasing chip production is a slow and difficult business.
Cryptocurrencies like Bitcoin have been billed as a major disruptor to finance. But digital currencies issued by governments might be even more radical—they may even threaten the future of traditional banking.
Read our special report, “The Future of Banking” : https://econ.st/3tuTT8y.
Sign up to our newsletter to keep up to date: https://econ.st/3a6aZmv.
Read more of our coverage on Finance & Economics: https://econ.st/3b0g3cs.
Listen to Economist’s podcast “Money Talks: the age of free money”: https://econ.st/3eUduK3
Is digital yuan set to transform both Chinese and international banking? https://econ.st/3eYqcYb.